GLOBUS MEDICAL, INC. (GMED) Quick Ratio
- Quick ratio · latest quarter: Value 2.69×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 2.69× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $1.29B ÷ $479.35M ≈ 2.69× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 1.29B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 479.35M USD | Liabilities, Current |
| Cash and equivalents | 507.75M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 87.40M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 692.18M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 810.90M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.29B | $479.35M | $507.75M | $87.40M | $692.18M | $810.90M | 2.69× |
| 2026-03-31 | $1.32B | $482.46M | $560.95M | $68.90M | $686.43M | $772.60M | 2.73× |
| 2025-12-31 | $1.24B | $498.50M | $526.16M | $31.09M | $678.94M | $759.28M | 2.48× |
| 2025-09-30 | (m) | $465.96M | (m) | $18.75M | $619.12M | $771.54M | (m) |
| 2025-06-30 | (m) | $424.66M | (m) | (m) | $611.57M | $772.13M | (m) |
| 2025-03-31 | (m) | $384.70M | (m) | (m) | $535.09M | $663.60M | (m) |
| 2024-12-31 | (m) | $855.91M | (m) | $105.62M | $557.70M | $659.23M | (m) |
| 2024-09-30 | (m) | $818.07M | (m) | $71.94M | $588.05M | $717.70M | (m) |
| 2024-06-30 | (m) | $794.15M | (m) | $82.51M | $611.78M | $770.46M | (m) |
| 2024-03-31 | (m) | $786.32M | (m) | $80.41M | $534.33M | $816.20M | (m) |
| 2023-12-31 | (m) | $392.35M | (m) | $50.50M | $503.24M | $848.13M | (m) |
| 2023-09-30 | (m) | $428.72M | (m) | $189.31M | $494.11M | $904.98M | (m) |
| 2023-06-30 | (m) | $155.22M | (m) | $306.38M | $240.18M | $335.56M | (m) |
| 2023-03-31 | (m) | $167.55M | (m) | $286.69M | $222.78M | $321.03M | (m) |
| 2022-12-31 | (m) | $159.20M | (m) | $295.59M | $213.25M | $298.98M | (m) |
| 2022-09-30 | (m) | $145.25M | (m) | $271.06M | $206.31M | $282.41M | (m) |
| 2022-06-30 | (m) | $146.02M | (m) | $257.24M | $192.81M | $266.04M | (m) |
| 2022-03-31 | (m) | $141.49M | (m) | $243.50M | $166.22M | $253.89M | (m) |
| 2021-12-31 | (m) | $140.16M | (m) | $250.38M | $164.44M | $237.00M | (m) |
| 2021-09-30 | (m) | $122.53M | (m) | $191.32M | $159.58M | $234.37M | (m) |
| 2021-06-30 | (m) | $130.04M | (m) | $191.64M | $165.85M | $231.21M | (m) |
| 2021-03-31 | (m) | $123.68M | (m) | $218.71M | $160.94M | $232.01M | (m) |
| 2020-12-31 | (m) | $120.79M | (m) | $187.34M | $141.68M | $229.15M | (m) |
| 2020-09-30 | $552.90M | $99.98M | $250.61M | $159.03M | $143.27M | $231.86M | 5.53× |
| 2020-06-30 | $448.83M | $106.13M | $165.55M | $151.18M | $132.09M | $224.46M | 4.23× |
| 2020-03-31 | $415.56M | $97.96M | $166.74M | $110.21M | $138.60M | $208.45M | 4.24× |
| 2019-12-31 | $465.56M | $111.40M | $195.47M | $115.76M | $154.33M | $196.31M | 4.18× |
| 2019-09-30 | $419.04M | $94.92M | $166.09M | $111.40M | $141.54M | $187.06M | 4.41× |
| 2019-06-30 | $385.11M | $84.18M | $117.79M | $122.64M | $144.68M | $173.04M | 4.57× |
| 2019-03-31 | $460.28M | $79.49M | $129.98M | $190.69M | $139.62M | $143.38M | 5.79× |
| 2018-12-31 | $476.65M | $96.12M | $139.65M | $199.94M | $137.07M | $131.25M | 4.96× |
| 2018-09-30 | $491.61M | $81.72M | $145.29M | $227.47M | $118.85M | $124.37M | 6.02× |
| 2018-06-30 | $479.48M | $80.28M | $119.94M | $240.98M | $118.56M | $114.76M | 5.97× |
| 2018-03-31 | $491.76M | $82.55M | $119.84M | $249.34M | $122.58M | $107.58M | 5.96× |
| 2017-12-31 | $490.38M | $93.07M | $118.82M | $254.89M | $116.68M | $108.41M | 5.27× |
| 2017-09-30 | $432.14M | $74.93M | $154.85M | $182.80M | $94.48M | $111.46M | 5.77× |
| 2017-06-30 | $407.68M | $69.06M | $149.67M | $162.52M | $95.49M | $111.11M | 5.90× |
| 2017-03-31 | $420.33M | $75.37M | $182.44M | $143.66M | $94.23M | $113.04M | 5.58× |
| 2016-12-31 | $382.30M | $79.89M | $132.64M | $157.67M | $91.98M | $112.69M | 4.79× |
| 2016-09-30 | $344.63M | $65.81M | $90.19M | $167.73M | $86.71M | $115.61M | 5.24× |
| 2016-06-30 | $399.23M | $70.28M | $95.34M | $229.17M | $74.71M | $104.42M | 5.68× |
| 2016-03-31 | $393.66M | $72.34M | $81.28M | $236.86M | $75.53M | $105.15M | 5.44× |
| 2015-12-31 | $358.71M | $82.69M | $60.15M | $220.88M | $77.68M | $105.26M | 4.34× |
| 2015-09-30 | $316.20M | $94.42M | $50.50M | $188.10M | $77.60M | $105.70M | 3.35× |
| 2015-06-30 | $272.85M | $91.73M | $41.56M | $158.25M | $73.05M | $101.05M | 2.97× |
| 2015-03-31 | $286.45M | $93.31M | $75.01M | $138.27M | $73.17M | $98.95M | 3.07× |
| 2014-12-31 | $304.13M | $89.41M | $82.27M | $146.44M | $75.43M | $90.94M | 3.40× |
| 2014-09-30 | $361.35M | $72.76M | $169.45M | $129.30M | $62.60M | $77.43M | 4.97× |
| 2014-06-30 | $341.32M | $65.97M | $136.50M | $139.76M | $65.05M | $76.36M | 5.17× |
| 2014-03-31 | $344.03M | $72.49M | $104.60M | $176.20M | $63.22M | $72.51M | 4.75× |
| 2013-12-31 | $301.34M | $67.94M | $89.96M | $148.96M | $62.41M | $70.35M | 4.44× |
| 2013-09-30 | $268.42M | $58.48M | $101.91M | $111.24M | $55.27M | $71.20M | 4.59× |
| 2013-06-30 | $218.69M | $56.63M | $92.31M | $68.84M | $57.53M | $71.36M | 3.86× |
| 2013-03-31 | $221.75M | $45.27M | $131.54M | $30.79M | $59.42M | $66.87M | 4.90× |
| 2012-12-31 | (m) | $39.51M | $212.40M | (m) | $53.50M | $62.31M | (m) |
| 2012-09-30 | (m) | $34.07M | $195.16M | (m) | $51.86M | $57.04M | (m) |
| 2012-06-30 | (m) | $29.02M | $165.58M | (m) | $49.48M | $53.12M | (m) |
| 2012-03-31 | (m) | (m) | $159.10M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $29.27M | $142.67M | (m) | $46.73M | $47.37M | (m) |
| 2011-09-30 | (m) | (m) | $127.33M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $107.75M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $111.70M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $50.65M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B |